Assessment of Biomarkers in asbestos-exposed workers as indicators of cancer risk

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 695, Issue 1-2, 2008, Pages 52-58

  Amati, Monica ^a   Tomasetti, Marco ^a   Mariotti, Laura ^a   Tarquini, Lucia Miria ^a   Valentino, Matteo ^a   Santarelli, Lory ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Asbestos exposure; Asbestos exposed workers; Biomarkers; Carcinogenic risk; Malignant mesothelioma

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANGIOGENIC FACTOR; ASBESTOS; DNA; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 6; MESOTHELIN; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; TUMOR MARKER; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER RISK; CELL TRANSFORMATION; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DNA ADDUCT; FEMALE; HUMAN; HUMAN CELL; INTERVIEW; JOB CHARACTERISTICS; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; POPULATION EXPOSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RISK ASSESSMENT; SMOKING; STEADY STATE; WORKPLACE; BLOOD; LYMPHOCYTE; MESOTHELIOMA; METABOLISM; MIDDLE AGED; OCCUPATIONAL DISEASE; PLEURA TUMOR; REGRESSION ANALYSIS; RISK FACTOR;

AGED; ASBESTOS; FEMALE; HUMANS; LYMPHOCYTES; MALE; MESOTHELIOMA; MIDDLE AGED; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PLEURAL NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149291810     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2008.06.011     Document Type: Article

References (38)

1. LaDou.F J. The asbestos cancer epidemic. Environ. Health Perspect. 2004, 112:285-290.
2. Tossavainen A. Global use of asbestos and the incidence of mesothelioma. Int. J. Occup. Environ. Health 2004, 10:22-25.
3. Mossman B.T., Bignon J., Corn M., Seabon A., Gee J.H.L. Asbestos: scientific development and implications for public policy. Science 1990, 247:294-301.
4. Adamson I.Y.R., Bakowska J., Bowden D.H. Mesothelial cell proliferation after instillation into mouse lung. Am. J. Pathol. 1993, 142:1209-1216.
5. Jaurand M.C. Mechanisms of fiber-induced genotoxicity. Environ. Health Perspec. 1997, 105S:1073-1084.
6. Okayasu R., Wu L., Hei T.K. Biological effects of naturally occurring and man-made fibers: in vitro cytoxicity and mutagenesis in mammalian cells. Br. J. Cancer 1999, 79:1319-1324.
7. IARC Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, International Agency for Research on Cancer, Lyon, France, 1987 (Suppl. 7).
8. World Health Organization, Asbestos and other natural mineral fibers, Environmental Health Criteria 53, World Health Organization, Genevra, Switzerland, 1986.
9. Sullivan P.A. Vermiculite, respiratory disease, and asbestos exposure in libby, Montana: update of a Cohort Mortality Study. Environ. Health Perspect. 2007, 115:579-585.
10. Lin R.T., Takahashi K., Karjalainen A., Hoshuyama T., Wilson D., Kameda T., Chan C.C., Wen C.P., Furuya S., Higashi T., Chien L.C., Ohtaki M. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 2007, 369:844-849.
11. Amati M., Tomasetti M., Scartozzi M., Mariotti L., Alleva R., Pienotti E., Borghi B., Valentino M., Governa M., Neuzil J., Santarelli L. Profiling tumour-associated markers for early detection of malignant mesothelioma: an epidemiological study. Cancer Epidemiol. Biomarkers Prev. 2008, 17:163-170.
12. Murphy R.L.H., Ferris B.G., Burgess W.A., Worcester J., Gaensler E.A. Effect of low concentration of asbestos: Clinical environmental, radiologic and epidemiological observations in shipyard pipe coverers and controls. N. Engl. J. Med. 1971, 285:1271.
13. Doll R., Peto J. Asbestos: Effects on Health of Exposure to Asbestos 1985, Health and Safety Commission, HMSO, London, United Kingdom.
14. Dusinská M., Collins A., Kazimírová A., Barancoková M., Harrington V., Volkovová K., Staruchová M., Horská A., Wsólová L., Kocan A., Petrík J., Machata M., Ratcliffe B., Kyrtopoulos S. Genotoxic effects of asbestos in humans. Mutat. Res. 2004, 553:91-102.
15. Marczynski B., Kraus T., Rozynek P., Raithel H.J., Baur X. Association between 8-hydroxy-2'-deoxyguanosine levels in DNA of workers highly exposed to asbestos and their clinical data, occupational and non-occupational confounding factors, and cancer. Mutat. Res. 2000, 468:203-212.
16. Otsuki T., Maeda M., Murakami S., Hayashi H., Miura Y., Kusaka M., Nakano T., Fukuoka K., Kishimoto T., Hyodoh F., Ueki A., Nishimura Y. Immunological effects of silica and asbestos. Cell Mol. Immunol. 2007, 4:261-268.
17. Chang K., Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:136-140.
18. Robinson B.W., Creaney J., Lake R., Nowak A., Musk A.W., de Klerk N., Winzell P., Hellstrom K.E., Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616.
19. Scherpereel A., Grigoriu B., Conti M., Gey T., Grégoire M., Copin M.C., Devos P., Chahine B., Porte H., Lassalle P. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 2006, 173:1155-1160.
20. Nishimura S.L., Broaddus V.C. Asbestos-induced pleural disease. Clin. Chest Med. 1998, 19:311-329.
21. Metintas M., Metintas S., Hillerdal G., Ucgun I., Erginel S., Alatas F., Yildirim H. Nonmalignant pleural lesions due to environmental exposure to asbestos: a field-based, cross-sectional study. Eur. Respir. J. 2005, 26:875-880.
22. Shiomi K., Hagiwara Y., Sonoue K., Segawa T., Miyashita K., Maeda M., Izumi H., Masuda K., Hirabayashi M., Moroboshi T., Yoshiyama T., Ishida A., Natori Y., Inoue A., Kobayashi M., Sakao Y., Miyamoto H., Takahashi K., Hino O. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin. Cancer Res. 2008, 14:1431-1437.
23. Huuskonen M.S., Rantanen J. Finnish Institute of Occupational Health (FIOH): prevention and detection of asbestos-related diseases, 1987-2005. Am. J. Ind. Med. 2006, 49:215-220.
24. Hemminki K., Li X. Time trends and occupational risk factors for pleural mesothelioma in Sweden. J. Occup. Environ. Med. 2003, 45:456-461.
25. Burdorf A., Dahhan M., Swuste P. Occupational characteristics of cases with asbestos-related diseases in The Netherlands. Ann. Occup. Hyg. 2003, 47:485-492.
26. Fontanini G., Vignati S., Bigini D., Lucchi M., Mussi A., Basolo F., Angeletti C.A., Bevilacqua G. Neoangiogenesis: a putative marker of malignancy in non-small cell lung cancer (NSCLC) development. Int. J. Cancer 1996, 67:615-619.
27. Fisseler-Eckhoff A., Rothstein D., Muller K.M. Neovascularisation in hyperplastic, metaplastic and potentially preneoplastic lesions of the bronchial mucosa. Virchows Arch. 1996, 429:95-100.
28. Kaygusuz G., Tulunay O., Baltaci S., Gogus O. Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue. Int. Urol. Nephrol. 2007, 39:841-850.
29. Strizzi L., Catalano A., Vianale G., Orecchia S., Casalini A., Tassi G., Puntoni R., Mutti L., Procopio A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 2001, 93:468-475.
30. Kumar-Singh S., Weyler J., Martin M.J., Vermeulen P.B., Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J. Pathol. 1999, 189:72-78.
31. Masood R., Kundra A., Zhu S., Xia G., Scalia P., Smith D.L., Gill P.S. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int. J. Cancer 2003, 104:603-610.
32. Tolnay E., Kuhnen C., Wiethege T., König J.E., Voss B., Müller K.M. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J. Cancer Res. Clin. Oncol. 1998, 124:291-296.
33. Langerak A.W., De Laat P.A., Van Der Linden-Van C.A., Beurden M., Delahaye, Van Der Kwast T.H., Hoogsteden H.C., Benner R., Versnel M.A. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J. Pathol. 1996, 178:151-160.
34. Hsu P.I., Chow N.H., Lai K.H., Yang H.B., Chan S.H., Lin X.Z., Cheng J.S., Huang J.S., Ger L.P., Huang S.M., Yen M.Y., Yang Y.F. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res. 1997, 17:2803-2809.
35. Takigawa N., Segawa Y., Fujimoto N., Hotta K., Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res. 1998, 18:1251-1254.
36. Griga T., Voigt E., Gretzer B., Brasch F., May B. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepatogastroenterology 1999, 46:920-923.
37. Chow N.H., Hsu P.I., Lin X.Z., Yang H.B., Chan S.H., Cheng K.S., Huang S.M., Su I.J. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Human Pathol. 1997, 28:698-703.
38. Giatromanolaki A., Koukourakis M.I., Comley M., Kaklamanis L., Turley H., O'Byrne K., Harris A.L., Gatter K.C. Platelet derived endothelial cell growth factor (thymidine phoshorylase) expression in lung cancer. J. Pathol. 1997, 181:196-199.